
Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

Your AI-Trained Oncology Knowledge Connection!


Ignacio Blanco, MD, PhD

Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.